- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05124405
Overvåke dine treningsrelaterte beregninger over tid via bærbare elektroniske enheter
To test the use of a continuous activity and heart rate tracker (Fitbit) and continuous glucose monitor (CGM) in monitoring daily exercise-related activities.
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
Primary objective:
To evaluate the feasibility of a CGM-based physical activity intervention that includes the use of CGM and Fitbit®.
Secondary objectives:
To examine changes in physical activity motivation and other related psychosocial variables (e.g., intention, perceived benefits, outcome expectancy) before and after the intervention.
Exploratory objective:
Examine cancer-related biomarkers and their associations with daily glucose pattern.
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
Texas
-
Houston, Texas, Forente stater, 77030
- M D Anderson Cancer Center
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Men and women at least 18 years old
- Body mass index (BMI) 25 kg/m2
- Engage in less than 150 minutes of moderate-intensity PA per week in the past month
- Capable of participating in moderate-vigorous unsupervised exercise (as determined by the Physical Activity Readiness Questionnaire (PARQ) or a medical release from their physician)
- Self-reported ability to walk one block without pain or discomfort
- Have a smart phone with daily internet access that is compatible with the LibreLink app
- Ability to speak, read, and write in English
- For the cancer survivor cohort (participant accession number #21 and beyond), individuals must have been diagnosed with stage I-III breast or colorectal cancer and completed adjuvant therapy (i.e., chemo and/or radiation therapy).
Exclusion Criteria:
- Self-reported current diagnosis or history of type 1 diabetes or type 2 diabetes
- Self-reported use of oral antidiabetic agents (OADs)
- Previous or current treatment with any insulin regimen other than basal insulin, e.g. prandial or pre-mixed insulin (short term treatment due to intercurrent illness including gestational is allowed at the discretion for the investigator)
- Current use of a continuous glucose monitor
- Fasting glucose > 125 mg/dL
- Pregnancy
- Self-reported health issues that limit physical activity
- On dialysis
- Work overnight shifts
- Unwilling to use CGM
- Current participation in other wellness or weight loss-related program or intervention
- Currently on a low-carb diet
- Unable to receive REDCap survey through their mobile phones
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Heart Rate Tracker (Fitbit)
continuous heart rate activity |
wearable activity tracker wearable activity tracker |
|
Eksperimentell: Continuous Glucose Monitor (CGM)
monitoring daily exercise-related activities |
wearable activity tracker wearable activity tracker |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
To evaluate the feasibility of the ( PA) Physical Activity intervention.
Tidsramme: through study completion, an average of 1 year
|
The use of CGM through the following criteria: CGM-specific refusal rate <20% at the participant recruitment phase and protocol adherence rates >80% at the end of the monitoring period. |
through study completion, an average of 1 year
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Karen Basen-Engquist, MD, M.D. Anderson Cancer Center
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 2018-0299
- NCI-2019-02652 (Annen identifikator: NCI-CTRP Clinical Trials Registry)
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .